Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.

Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.

BACKGROUND:Inflammation has been associated with increased morbidity and mortality in HIV-positive patients. We compared inflammatory biomarkers with dual therapy using lopinavir/ritonavir plus lamivudine (LPV/r+3TC) versus triple therapy using LPV/r plus two nucleoside reverse transcriptase inhibit...

Full description

Bibliographic Details
Main Authors: Darrell H S Tan, Maria Jose Rolon, Maria Ines Figueroa, Omar Sued, Ana Gun, Rupert Kaul, Janet M Raboud, Leah Szadkowski, Mark W Hull, Sharon L Walmsley, Pedro Cahn, Argentinean GARDEL research network
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0221653

Internet

https://doi.org/10.1371/journal.pone.0221653

Similar Items